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INTRODUCTION
Although acute flexor tendon injuries are relatively uncom-
mon, restoration of hand function following such trauma has 
been challenging.1-3 Adhesions may form between the repaired 
tendons and surrounding tendon sheath, especially in the tight 
fibro-osseous spaces of zone II injuries, despite meticulous 
surgical techniques and aggressive postoperative therapy.4,5 
Several innovative approaches to prevent adhesion formation 
after tendon repair have been proposed, including anti-inflam-
matory agents, such as steroids and non-steroidal anti-inflam-
matory drugs;6,7 natural polymers, such as hyaluronic acid,8-10 
collagen solution,11 and amniotic fluid;11 anti-metabolites, such 
as 5-fluorouracil;12,13 and barrier methods ,such as polytetraflu-
oroethylene membrane and porcine gelatin.14,15 However, these 
anti-adhesion therapies remain unsuccessful and have not 
progressed beyond preclinical studies.
It has been shown that the transforming growth factor-beta 
(TGF-β) pathway is involved in the formation of adhesions.16 
Studies on TGF-β pathway inhibition have reported an im-
provement in the range of digital motion as well as alteration 
of types I, III, and V collagen production.17,18 In vitro studies us-
ing the natural TGF-β inhibitors decorin and mannose 6-phos-
phate (M6P) have reported a reduction in TGF-β induced col-
Follistatin Mitigates Myofibroblast Differentiation and 
Collagen Synthesis of Fibroblasts from Scar Tissue 
around Injured Flexor Tendons
Young-Mi Kang1,2*, Su-Keon Lee2*, Yong-Min Chun2, Yun-Rak Choi2, 
Seong-Hwan Moon1,2, Hwan-Mo Lee2, and Ho-Jung Kang2
1BK21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul; 
2Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Purpose: The aim of this study was to investigate the effect of FST gene on the inhibition of fibrosis in fibroblastic cells from scar 
tissue around repaired zone II flexor tendons.
Materials and Methods: Immunohistochemistry was conducted on fibroblast cells transfected with adenovirus-LacZ (Ad-LacZ) 
as a marker gene (control), or with adenovirus-FST (Ad-FST) as a therapeutic gene. Fibroblast cultures without adenoviral expo-
sure served as controls.
Results: Fibroblastic cells transfected with Ad-FST demonstrated significant decrease in collagen type I, MMP-1, MMP2, and 
α-SMA mRNA expressions compared to those transfected with Ad-LacZ. In addition, fibroblastic cells transfected with Ad-FST 
exhibited significant decrease in MMP-1, TIMP-1, fibronectin, PAI-1, TRPV4, α-SMA, desmin, and PAX7 protein expressions.
Conclusion: Based on these findings, we conclude that FST may be a novel therapeutic strategy for preventing scar adhesions 
around repaired tendons by inhibiting fibroblasts from differentiating into myofibroblasts, in addition to producing type I colla-
gen and regulating extracellular matrix turnover via the downregulation of MMP-1 and TIMP-1. FST may also decrease contrac-
ture of the scar by inhibiting Ca2+-dependent cell contraction.
Key Words:  Follistatin, tendon injuries, tendon adhesion, fibrosis, gene therapy
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: August 14, 2019   Revised: October 3, 2019
Accepted: October 7, 2019
Corresponding author: Yun-Rak Choi, MD, PhD, Department of Orthopaedic Sur-
gery, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea.
Tel: 82-2-2228-2180, Fax: 82-2-363-1139, E-mail: YRCHOI@yuhs.ac
*Young-Mi Kang and Su-Keon Lee contributed equally to this work.
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2020
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2020 Jan;61(1):85-93
https://doi.org/10.3349/ymj.2020.61.1.85
86
Follistatin’s Effect on Tendon Adhesion
https://doi.org/10.3349/ymj.2020.61.1.85
pENTER
7510 bp pAD-Amp
34200 bp
DAPI Ad-FST
TGF-β1+/FST+
Left arm
Right arm
Left arm
ITR
ITR
CMV
MCS
T7
pBR322 origin
Kanamycin
SV40
Puromycin
I-Sce I
Pme 1
AsiS I
Asc I
Rsr II
Mlu I
Not I
Xho I
SV40 PolyA
Swa I
Pac 1
Pac 1
Swa I
Pme 1
I-Sce I
pBR322
Amp
Right arm
130
98
65
33
0
TGF-β1 + +
Ad-FST – +
In
te
ns
ity
 o
f a
d-
FS
T 
ex
pr
es
sio
n
lagen production, especially type I collagen.19 However, other 
studies have reported that TGF-β pathway inhibition is associ-
ated with a decrease in mechanical strength,20,21 and a clinical 
trial on M6P did not demonstrate any beneficial effect on fin-
ger movements.22 
It has been reported that activin A in fibroblasts, which is 
induced by TGF-β1, stimulates inflammation and fibrosis in 
many different models, including inflammatory bowel dis-
ease, rheumatoid arthritis, and wound healing, and following 
burn injuries.23,24 A key regulator of activin is follistatin (FST), 
a glycoprotein that binds activin. This binding is virtually irre-
versible. The resulting complex targets a lysosomal degrada-
tion pathway.25 FST can block the fibrogenic actions of TGF-β 
despite its inability to bind TGF-β1, suggesting that TGF-β1 
exerts fibrogenic actions through its stimulation of activin A.24 
In addition, as FST binds to activin A, it attenuates the capacity 
of activin A to stimulate fibrosis, as demonstrated in hepatic fi-
brosis,26 pulmonary fibrosis,27 and radiation-induced fibrosis.28 
In this study, we hypothesized that the activin/FST pathway 
offers a novel biological target for preventing the formation of 
tendon adhesions. We used an adenovirus system to transfer 
a follistatin gene construct into fibroblasts isolated from scar 
tissue around the repaired flexor tendons of patients who un-
derwent tenolysis after repair of zone II tendon. The goal of 
this experiment was to investigate the effect of this gene on in-
hibition of fibrosis.
MATERIALS AND METHODS
The Human Subjects Institutional Review Board of Yonsei Uni-
versity Health System, Severance Hospital (4-2016-0174) ap-
proved all of the experimental protocols in this study.
Study design
To test the anti-fibrotic effect of adenovirus-FST construct 
(Ad-FST) on fibroblasts in vitro, we utilized cells from the scar 
tissue of patients who underwent tenolysis following repair of 
zone II flexor tendons. Fibroblasts were activated by TGF-β1 (2 
ng/mL), exposed to Ad-FST as a therapeutic gene and adeno-
virus-LacZ construct as a marker gene, and cultured for 24 
hours. The second set of fibroblast cultures that were not ex-
posed to Ad-FST or Ad-LacZ served as the control. The mRNA 
expression levels of collagen types I, III, IV, V, and XI, as well as 
MMP-1, -3, -8, -9, and -13 were analyzed by reverse-transcrip-
tion polymerase chain reaction (RT-PCR). In addition, protein 
expression levels of fibronectin, PAI-1, TRPV4, MMP-1, -2, -13, 
TIMP-1, -2, -4, and alpha-smooth muscle actin (α-SMA) were 
estimated using Western blot analysis.
Isolation and cell culture 
Scar tissues around the repaired zone II flexors were harvest-
ed from seven patients, in whom adhesions had formed be-
tween the tendon and its sheath during tenolysis. Minced tis-
sues were digested at 37°C under gentle agitation with type IV 
collagenase (250 unit/mL; Sigma, St. Louis, MO, USA). Cells 
were placed in culture plates (TPP, Trasadingen, Switzerland) 
Fig. 1. Recombinant adenovirus was transfected in fibroblast from the scar tissue of patients with adhesions around zone II flexor tendon after tendon 
repair by immunocytochemistry analysis, indicating highly efficient transduction rate of adenoviral marker gene construct when activated by trans-
forming growth factor-beta 1 (TGF-β1). ‘+’ means ‘treatment’ and ‘–’ means ‘no treatment’. Ad-FST, adenovirus follistatin gene construct; DAPI, 4',6-di-
amidino-2-phenylindole.
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Fig. 2. Gene expressions of collagen I (A), collagen III (B), collagen IV (C), collagen V (D), and collagen XI (E) in fibroblast from adhesion tissue in patients with 
zone II flexor tendon repair and transfection with/without adenovirus follistatin gene construct (Ad-FST). Expression of collagen type I mRNA in fibroblast with 
Ad-FST showed a 25% decrease at 24 hours compared to control culture (TGF-β1+). ‘+’ means ‘treatment’ and ‘–’ means ‘no treatment’. *p<0.05. TGF-β1, 
transforming growth factor-beta 1; Ad-LacZ, adenovirus LacZ gene construct; SB505124, selective inhibitor of transforming growth factor-β type I receptor.
at 4×105 cells/mL. Primary cultures were sustained for 2–3 
weeks in Dulbecco’s Modified Eagle Medium (DMEM; Life 
Technologies Corporation, Carlsbad, CA, USA) containing 
10% fetal bovine serum, 1% v/v penicillin, streptomycin, and 
nystatin (Life Technologies Corporation) in a 37°C incubator 
with 5% CO2 and humidity. The isolated primary cells at pas-
sage 1 were subcultured at a 1:3 ratio when they were 80–90% 
confluent, up to P3, which were stored at -80°C until being used.
Follistatin constructs and transfections
For this study, Ad-FST expressing the human follistatin gene 
was prepared, and Ad-LacZ expressing the LacZ gene was 
used as a viral control. Each recombinant adenoviral vector 
originated from replication-deficient adenovirus type 5 lack-
ing E1 and E3 regions (Fig. 1). FST gene was cloned into the 
E1 region under the control of human cytomegalovirus early 
promoter. Recombinant virus was grown in transformed hu-
man embryonic kidney 293 (HEK293) cells and purified with 
Vivapure AdenoPACK 100 (Sartorius Stedim Biotech, Goettin-
gen, Germany). Titers were determined by optical density at 
260 nm. At confluence, fibroblastic cells were rinsed with Dul-
becco’s phosphate buffered saline (PBS; Life Technologies Cor-
poration), and then exposed to DMEM containing one dose of 
Ad-LacZ or Ad-FST with a viral infection multiplicity of 80.
RT-PCR analysis for matrix metalloproteinases and 
collagens
Total RNA was isolated from the fibroblasts transfected with 
Ad-FST for 24 hours using QIAGEN RNeasy mini kit (QIAGEN, 
Germantown, MD, USA). In addition, cDNA was prepared us-
ing QuantiTect Reverse Transcription Kit (QIAGEN). Collagen 
and MMP genes were amplified, and relative expressions 
were normalized to the average beta-actin levels. Resulting 
data were analyzed using ImageJ software version 1.6 (Na-
tional Institutes of Health, Bethesda, MD, USA).
Protein extraction and Western blot analysis
Fibroblasts at a density of 2×105 cells per well were transfected 
with Ad-FST for 24 hours and lysed in RIPA lysis buffer (ATTO 
Corp., Tokyo, Japan) containing protease inhibitor (Pierce Mini 
Tablets, IL, USA). Meanwhile, the culture medium was col-
lected to measure FST protein expression by Ad-FST. Lysates 
and culture medium were separated by sodium dodecyl sul-
fate-polyacrylamide gel electrophoresis, and proteins were 
then transferred to polyvinylidene difluoride membranes 
(Merck Millipore Ltd., Darmstadt, Germany) using a transfer 
system (Mini Trans-Blot Cell and systems, Bio-Rad, Hercules, 
CA, USA). The blots were incubated with specific antibodies 
against MMP-1, MMP-13, TIMP-1, TIMP-2, TIMP-4, fibronec-
tin, PAI-1, TRPV4, and α-SMA (Abcam, Cambridge, UK). After 
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Fig. 3. Gene expressions of MMP-1 (A), MMP-2 (B), MMP-3 (C), MMP-9 (D), and MMP-13 (E) in fibroblast from adhesion tissue in patients with zone II 
flexor tendon repair and transfection with/without adenovirus follistatin gene construct (Ad-FST). Expressions of MMP-1 and -2 mRNA in fibroblast 
with Ad-FST showed a 31% and 59% decrease, respectively, at 24 hours compared to control culture (TGF-β1+). ‘+’ means ‘treatment’ and ‘–’ means ‘no 
treatment’. *p<0.05. TGF-β1, transforming growth factor-beta 1; MMP, matrix metalloproteinase; Ad-LacZ, adenovirus LacZ gene construct; SB505124, 
selective inhibitor of transforming growth factor-β type I receptor. 
reacting with secondary antibodies, immunoreactive bands 
were visualized by a Western blot detection system (EzWest-
Lumi Plus, ATTO Corp., Japan). To verify the amounts of load-
ed proteins, blots were stripped of bound antibodies and re-
probed using antibodies to actin (Abcam).
Immunocytochemistry 
The cells were transfected with Ad-FST for 24 hours at a den-
sity of 2×105 cells per well in culture medium, and fixed in 4% 
formaldehyde. The cells were then permeabilized in 0.1% Tri-
ton X-100 (SIGMA, St. Louis, MO, USA) for 20 minutes, and 
incubated in PBS with 1% bovine serum albumin for 1 hour. 
The cells were incubated with antibodies overnight at 4°C. The 
secondary antibodies (stained in red and green) were used at 
a 1:1000 dilution for 1 hour. DAPI was used to stain the cell 
nuclei (blue).
Statistical analyses
All data are expressed as the mean±standard deviation com-
piled from three independent experiments of separate cul-
tures isolated from seven donors. A two-tailed Student’s t-test 
was used to compare the means of the two groups. A p val-
ue<0.05 was considered statistically significant.
RESULTS
FST protein expression from Ad-FST transfected 
fibroblasts
Fibroblasts from the scar tissue of patients with adhesions 
around a repaired zone II flexor tendon that were transfected 
with Ad-FST showed increased staining of FST protein on con-
focal images compared to fibroblasts transfected with a control 
(Fig. 1), indicating that FST gene construct was efficiently trans-
duced into the fibroblasts.
Expression of collagen type I, MMP-1, and MMP-2 
mRNAs
Fibroblasts transfected with Ad-FST exhibited a significant 
(25%) decrease in collagen type I mRNA expression at 24 hours 
compared to Ad-LacZ controls (TGF-β1+) (p=0.003) (Fig. 2). 
Fibroblasts transfected with Ad-FST also exhibited significant 
decrease in MMP-1 and MMP-2 mRNA expressions (31% and 
59%, retrospectively) at 24 hours compared to Ad-LacZ controls 
(TGF-β1+) (Fig. 3). The expression of α-SMA mRNA also was 
significantly decreased (23%) in fibroblasts transfected with 
Ad-FST at 24 hours compared to Ad-LacZ controls (TGF-β1+) 
(p=0.001) (Fig. 4). The effect of TGF-β1 on these fibroblasts did 
not change when treated with a selective small molecule in-
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hibitor, SB505124, of the canonical (i.e., Smad-dependent) 
TGF-β signaling pathway. These findings suggest that fibro-
blasts may be activated by TGF-β1 via the non-canonical TGF-β 
signaling pathway.
Expression of MMP-1, TIMP-1, fibronectin, PAI-1, 
TRPV4, and α-SMA
Fibroblasts transfected with Ad-FST exhibited significant de-
crease in MMP-1, TIMP-1, and fibronectin (24%, 23%, and 
24%, retrospectively) at 24 hours compared to Ad-LacZ con-
trols (TGF-β1+) (p<0.001, p=0.002, p<0.001, retrospectively) 
(Figs. 5 and 6). Fibroblasts transfected with Ad-FST also dem-
onstrated significant inhibition of TRPV4, PAI-1, and α-SMA 
protein expressions (23%, 23%, and 28%, retrospectively) at 24 
hours compared to Ad-LacZ controls (TGF-β1+) (p=0.002, p< 
0.001, p=0.002, retrospectively) (Fig. 7). 
Immunocytochemistry analysis of α-SMA, desmin, 
and PAX7
Fibroblasts with Ad-FST exhibited decrease in α-SMA, desmin, 
and PAX7 expressions compared to Ad-LacZ controls (Fig. 8).
DISCUSSION
Following repair, tendons heal via both intrinsic and extrinsic 
pathways. Intrinsic healing involves the proliferation of teno-
cytes and the production of extracellular matrix (ECM).29 Ex-
trinsic healing involves an invasion of cells from the surround-
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Fig. 5. Protein expressions of MMPs (A), MMP-1 (B), MMP-2 (C), and MMP-13 (D) in fibroblast from adhesion tissue in patients with zone II flexor ten-
don repair and transfection with/without adenovirus follistatin gene construct (Ad-FST). Expression of MMP-1 protein in fibroblast with Ad-FST showed 
a 24% decrease at 24 hours compared to control culture (TGF-β1+). ‘+’ means ‘treatment’ and ‘–’ means ‘no treatment’. *p<0.05. TGF-β1, transforming 
growth factor-beta 1; MMP, matrix metalloproteinase; Ad-LacZ, adenovirus LacZ gene construct; SB505124, selective inhibitor of transforming growth 
factor-β type I receptor.
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Fig. 4. Gene expressions of PAI-1 (A) and α-SMA (B) in fibroblast from 
adhesion tissue in patients with zone II flexor tendon repair and trans-
fection with/without adenovirus follistatin gene construct (Ad-FST). Ex-
pression of α-SMA mRNA in the fibroblast with Ad-FST showed a 23% 
decrease at 24 hours compared to control culture (TGF-β1+).  ‘+’ means 
‘treatment’ and ‘–’ means ‘no treatment’. *p<0.05. TGF-β1, transforming 
growth factor-beta 1; Ad-LacZ, adenovirus LacZ gene construct; SB505124, 
selective inhibitor of transforming growth factor-β type I receptor.
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Fig. 6. Protein expressions of TIMP-1, -2, -4 (A-D) and fibronectin (E) in fibroblast from adhesion tissue in patients with zone II flexor tendon repair and 
transfection with/without adenovirus follistatin gene construct (Ad-FST). Expressions of TIMP-1 and fibronectin protein in fibroblast with Ad-FST 
showed a 23% and 24% decrease, respectively, at 24 hours compared to control culture (TGF-β1+). ‘+’ means ‘treatment’ and ‘–’ means ‘no treatment’. 
*p<0.05. TGF-β1, transforming growth factor-beta 1; Ad-LacZ, adenovirus LacZ gene construct; SB505124, selective inhibitor of transforming growth 
factor-β type I receptor. 
ing sheath and synovium, which envelop the tendon structure 
and contribute to the formation of adhesions.29 Extrinsic heal-
ing dominates when the tendon or tendon sheath is injured, 
as the tendon has poor cell density and growth factor activity. 
Although several approaches have been proposed to prevent 
the formation of adhesions, there is limited evidence to prove 
that these approaches are successful, and none has been widely 
accepted for clinical use.30 Since tendon injury stimulates in-
creased expression of TGF-β1 in the production of collagen 
types I and III, fibronectin, and glycosaminoglycans,31 blocking 
TGF-β1 has been reported to decrease tendon adhesion in ani-
mal tendon injury models. However, blocking TGF-β1 can also 
result in reduced tendon strength, as another role of TGF-β1 is 
to modulate immune responses and tissue repair.16,20,32 There-
fore, it is necessary to investigate methods that can selectively 
isolate and block the pro-fibrosis effects of TGF-β1.
FST, a systemically-expressed circulating glycoprotein, is 
the endogenous ligand-binding partner for activin A.33 It is 
well-recognized that FST can inhibit the activity of activin A, 
which is overexpressed in TGF-β1-induced fibrosis.24,34 In the 
present study, the anti-fibrotic effect of FST was investigated 
via genetic modification of fibroblastic cells from patients 
with zone II flexor tendon adhesion after tendon repair. We 
found that fibroblastic cells from scar adhesion tissue trans-
fected with Ad-FST showed decrease in expression levels of 
collagen type I mRNA, compared to fibroblasts transfected 
with Ad-LacZ controls. These findings indicate that FST gene 
inhibits the transcription of collagen type I. We also showed 
that the inserted FST gene decreased both transcription and 
translation of MMP-1 and TIMP-1. Tissue inhibitors of metal-
loproteinases (TIMPs) are pleiotropic extracellular proteins, 
and are recognized as endogenous regulators of matrix metal-
loproteinases (MMPs), which comprise a large family of extra-
cellular enzymes with proteolytic activities that participate in 
cellular homeostasis, adaptation, and tissue remodeling.35 
The findings of the present study suggest that FST restores the 
pathological imbalance of ECM turnover from zone II flexor 
tendon adhesions via the downregulation of MMP-1 and TIMP-
1, which may contribute to the decrease in scar formation.
It is now accepted that myofibroblasts go through a precur-
sor stage, in which large stress fibers are expressed. These large 
stress fibers are not observed in quiescent fibroblasts. These 
prominent bundles of microfilaments permit some contrac-
tion, pre-stressing, and remodeling of the surrounding ECM.36 
At a later stage, fully differentiated myofibroblasts exhibit ex-
pression of α-SMA, which is usually an SM-specific cytoskele-
tal protein and is often used to define the myofibroblast phe-
notype.37 In the present study, the synthesis of fibronectin, a 
non-collagenous protein, as well as PAI-1 and α-SMA, were 
suppressed in fibroblasts transfected with Ad-FST compared 
to Ad-LacZ controls at protein level. The significant decrease 
in α-SMA expression suggests that FST may inhibit the trans-
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formation of fibroblasts to myofibroblasts. The decrease in tran-
scription of collagen type I gene may also be associated with a 
decrease in the transformation of fibroblasts to myofibroblasts. 
In the present study, the synthesis of TRPV4 was suppressed 
at protein level in fibroblasts transfected with Ad-FST com-
pared to Ad-LacZ controls. It has been proposed that myofi-
broblasts contract via Ca2+-dependent mechanisms similar to 
those present in smooth muscle cells, with increased free Ca2+ 
regulating the phosphorylation of myosin light chain.38 The 
findings from our study suggest that FST may decrease the con-
traction of fibroblasts from tendon adhesion tissue by sup-
pressing the translation of TRPV4.
In conclusion, FST may be a novel therapeutic strategy for 
preventing scar adhesions around repaired tendons by inhib-
iting fibroblasts from differentiating into myofibroblasts, as well 
as producing type I collagen and regulating ECM turnover via 
the downregulation of MMP-1 and TIMP-1. Due to the lack of 
knowledge regarding FST on tenocytes after tendon injury, fur-
ther studies should be performed on how FST would affect ten-
don healing and strength when tenocytes are tested. FST may 
also decrease the contracture of the scar produced from myofi-
broblasts by inhibiting Ca2+-dependent contraction of the cells. 
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